Quarterly Updates14 Aug 2025, 06:17 pm
AstraZeneca Pharma India Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies
AI Summary
AstraZeneca Pharma India Limited announced its financial results for the quarter ended June 30, 2025. The company reported a revenue increase of 36% compared to the same period last year, supported by strategic execution, regulatory milestones, and continued portfolio expansion. The therapy areas showed consistent growth, with Oncology leading at 3702.7 INR Mn and Biopharmaceuticals at 1183.2 INR Mn.
Key Highlights
- Revenue increased by 36% in Q1 2025-26
- Four new approvals reinforced leadership in Oncology
- Received CDSCO approval for additional indications in Oncology and other therapy areas
- Awarded OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials
- Featured by Fortune India as a leading multinational transforming healthcare in India